Imohl M, Reinert RR, van der Linden M (2010) Regional differences in serotype distribution, pneumococcal vaccine coverage, and antimicrobial resistance of invasive pneumococ- cal disease among German federal states. Int J Med Microbiol 300(4):237-247...
As the incidence of childhood IPD by vaccine serotype declined with the national immunization program (NIP) involving PCV, the proportion of non-vaccine serotypes in IPD began to increase in the early 2000s as a natural consequence [57,58], called “serotype replacement”. PCV also reduced car...
- 《Vaccine》 被引量: 14发表: 2015年 Bacteremia in Children 3 to 36 Months Old After Introduction of Conjugated Pneumococcal Vaccines BACKGROUND AND OBJECTIVES: In June 2010, Kaiser Permanente Northern California replaced all 7-valent pneumococcal conjugate vaccine (PCV7) vaccines with the 13-...
The primary endpoint of serotype-specific IgG concentration is measured at 18 months of age. The primary endpoint of YF vaccine response is measured 1 month post YF vaccination in the co-administration and separate administration groups. Timing of secondary endpoint assessments Secondary endpoints of ...
Data support NZ adapting their national immunization program (NIP) to include the PCV13, which is the primary vaccine administered for IPD in Australia, according to the investigators. “Several countries have not seen an increase in serotype 19A after PCV13 implementation in the immunization program...
Herd effects from higher-valent PCVs in childhood (12/26), serotype replacement (2/26), or both (1/26) were included in half (13/26) of studies, which attenuated adult vaccine impact. Most studies were assessed as low risk of bias; five abstracts did not provide sufficient information ...
Pneumococcal conjugate vaccine had an efficacy rate of 97 % against invasive pneumococcal disease with vaccine serotypes, and a 93 % efficacy rate for disease with any serotype. Children who received the pneumococcal vaccine were 1/3 less likely to develop x-ray confirmed pneumonia compared to ...
A number of vaccine manufacturers are currently developing polysaccharide conjugate vaccines for various Streptococcus pneumoniae serotypes. In order to allow comparisons between conjugate vaccines, it is important that the assays used to quantitate the human antibody response to the PnPs serotypes measure...
Although mean efficacy of multivalent pneumococcus vaccines has been intensively studied, variance in vaccine efficacy (VE) has been overlooked. Different net individual protection across settings can be driven by environmental conditions, local serotype
Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites PLoS Med, 10 (2013), p. e1001517 CrossrefView in ScopusGoogle Scholar 15 PC Wroe, GM Lee, JA Finkelstein, et al. Pneumococcal carriage and...